RenovaCare, Inc.

RenovaCare, Inc.

RCAR
RenovaCare, Inc.US flagOther OTC
0.00
USD
- -
- -
8,735.00Market Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
0.02
-0.07
0.07
- -
-0.02
-0.03
-0.02
-0.03
-0.05
-0.03
-0.04
-0.11
-0.05
-0.07
Free Cash Flow per Basic Share
-0.01
-0.01
-0.02
- -
-0.01
-0.01
-0.02
-0.03
-0.02
-0.03
-0.04
-0.05
-0.05
-0.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.07
-0.14
-0.07
-0.07
-0.09
-0.11
-0.13
-0.16
-0.2
-0.22
-0.23
-0.34
-0.39
-0.44
Tangible Book Value per Share
0.02
-0.05
0.02
0.02
0.02
- -
- -
- -
0.02
0.2
0.14
0.08
0.03
-0.02
Basic Weighted Avg Shares
63
63
63
63
63
67
67
70
74
78
87
87
87
87
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-594.54
-971.25
-2,407.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
1
-4
4
- -
-1
-2
-1
-2
-4
-2
-3
-10
-4
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
2,482.79
-10,707.79
13,595.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
1
-3
1
- -
1
- -
- -
- -
3
15
12
7
2
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
1
Total Equity
1
-3
1
1
2
- -
- -
- -
2
15
12
7
2
-1
Return on Invested Capital (%)
- -
- -
77.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-68.84
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
- -
- -
- -
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
87
87
Market Capitalization
22
6
4

Working Capital

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
3
1
1
Cash, Cash Equivalents & STI
2
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
122.4%
257.4%
-66.85%
Free Cash Flow
28.19%
23.44%
-4.21%
Net Income, GAAP
56.82%
44.91%
-53.17%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.01
-0.03
-0.03
- -
-0.11
2021
-0.01
-0.01
-0.02
- -
-0.05
2022
-0.02
-0.03
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Harmel Singh Rayat
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
9375 East Shea Blvd Scottsdale AZ United States of America 85260
IPO Date
May 30, 1996
Business
RenovaCare, Inc. is a biotechnology and medical device firm engaged in the investigation, advancement, and commercialization of autologous cellular therapies for diverse medical and aesthetic uses. The company primarily focuses on the regeneration of human skin, the body's largest organ, and is developing its patented CellMist System and SkinGun technology. The CellMist System is designed to isolate stem cells from a patient's own skin, which are then gently applied to affected areas using the SkinGun, a specialized spray device, to promote natural wound healing. This innovative approach targets patients with burns, chronic and acute wounds, and scars, aiming to offer a swift and less invasive alternative to conventional skin grafting methods. In recent developments, RenovaCare received full Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration in May 2021 to conduct a clinical trial, designated CELLMIST 1, assessing the safety and feasibility of its SkinGun and CellMist System for treating burn wounds. However, patient enrollment for this trial was later paused in March 2022, influenced by lower-than-anticipated participation rates and ongoing legal challenges. The company also terminated its strategic research and development agreement with StemCell Systems GmbH in May 2022, which led to the closure of its R&D center in Berlin, Germany. The company, headquartered in Scottsdale, Arizona, continues to maintain its patent portfolio and intends to resume clinical development when additional funding becomes available. RenovaCare, Inc. was initially known as Janus Resources, Inc. before adopting its current name in January 2014.

Company News

APIChatGPT
  • Contrasting Biofrontera (NASDAQ:BFRI) & RenovaCare (OTCMKTS:RCAR)

  • RenovaCare (OTCMKTS:RCAR) Stock Crosses Above 50 Day Moving Average – Time to Sell?

  • RenovaCare Inc. Provides Notice of Proposed Derivative Settlement to All Record Holders and Beneficial Owners of RenovaCare, Inc.

  • Hagens Berman Sobol Shapiro LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of RenovaCare Securities - RCAR

  • RenovaCare Announces Termination of StemCell Systems R&D Agreement

  • SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating RenovaCare, Inc.

  • RenovaCare Announces Management Changes

  • RenovaCare Provides Clinical and Corporate Update

  • RM LAW Announces Investigation of RenovaCare, Inc.

  • SHAREHOLDER ALERT: Robbins LLP Investigates RenovaCare, Inc. (RCAR) on Behalf of Investors

  • RENOVACARE ALERT: Bragar Eagel & Squire, P.C. is Investigating RenovaCare, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • RCAR Long-Term Investor Alert: Did You Acquire RenovaCare, Inc. Before August 14, 2017? Should Management be Held Accountable for Investors Losses?

  • Last Few Hours to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of RenovaCare, Inc. (RCAR) Class Action and Lead Plaintiff Deadline: September 14, 2021

  • Last Few Hours to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of RenovaCare, Inc. (RCAR) Class Action and Lead Plaintiff Deadline: September 14, 2021

  • RCAR Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages RenovaCare, Inc. Investors with Losses to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR

  • RCAR Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages RenovaCare, Inc. Investors with Losses to Secure Counsel Before Important September 14 Deadline in Securities Class Action - RCAR

  • DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

  • DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against RenovaCare, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm